Rank #1251IOVA

Iovance Biotherapeutics, Inc.

$2.85

4.78% (Daily)

Market Cap

$1.13B

Revenue

$250.42M

Rank by MCap

#1251

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Frederick G. Vogt Esq., J.D., Ph.D.

Headquarters

San Carlos, CA

Employees

838

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic mela...